Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness.

Mizrachi T, Brill L, Rabie M, Nevo Y, Fellig Y, Zur M, Karussis D, Abramsky O, Brenner T, Vaknin-Dembinsky A.

J Immunol Res. 2018 May 22;2018:5389282. doi: 10.1155/2018/5389282. eCollection 2018.

2.

Development of a Novel Backbone Cyclic Peptide Inhibitor of the Innate Immune TLR/IL1R Signaling Protein MyD88.

Dishon S, Schumacher A, Fanous J, Talhami A, Kassis I, Karussis D, Gilon C, Hoffman A, Nussbaum G.

Sci Rep. 2018 Jun 21;8(1):9476. doi: 10.1038/s41598-018-27773-8.

3.

Low-Density Lipoprotein Receptor-Related Protein 4-Positive Myasthenia Gravis in a Double-Seronegative, Electromyography-Negative Patient.

Kruger JM, Karussis D, Zisimopoulou P, Petrou P.

J Neuroophthalmol. 2017 Sep;37(3):285-286. doi: 10.1097/WNO.0000000000000499.

PMID:
28350570
4.

T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO).

Vaknin-Dembinsky A, Brill L, Kassis I, Petrou P, Ovadia H, Ben-Hur T, Abramsky O, Karussis D.

Mult Scler Relat Disord. 2016 Mar;6:28-36. doi: 10.1016/j.msard.2015.12.004. Epub 2015 Dec 11.

PMID:
27063619
5.

Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel.

Brill L, Mandel M, Karussis D, Petrou P, Miller K, Ben-Hur T, Karni A, Paltiel O, Israel S, Vaknin-Dembinsky A.

J Neuroimmunol. 2016 Apr 15;293:65-70. doi: 10.1016/j.jneuroim.2016.02.006. Epub 2016 Feb 15.

PMID:
27049564
6.

Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.

Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D.

JAMA Neurol. 2016 Mar;73(3):337-44. doi: 10.1001/jamaneurol.2015.4321.

PMID:
26751635
7.

Sex-specific prediction of interferon beta therapy response in relapsing-remitting multiple sclerosis.

Charbit H, Benis A, Geyshis B, Karussis D, Petrou P, Vaknin-Dembinsky A, Lavon I.

J Clin Neurosci. 2015 Jun;22(6):986-9. doi: 10.1016/j.jocn.2014.11.027. Epub 2015 Apr 14.

PMID:
25882258
8.

Tumefactive demyelination following in vitro fertilization (IVF).

Vaknin-Dembinsky A, Bdolah Y, Karussis D, Rosenthal G, Petrou P, Fellig Y, Abramsky O, Lossos A.

J Neurol Sci. 2015 Jan 15;348(1-2):256-8. doi: 10.1016/j.jns.2014.11.016. Epub 2014 Nov 18.

PMID:
25499758
9.
10.

Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?

Brill L, Goldberg L, Karni A, Petrou P, Abramsky O, Ovadia H, Ben-Hur T, Karussis D, Vaknin-Dembinsky A.

Mult Scler. 2015 Apr;21(5):572-9. doi: 10.1177/1352458514551779. Epub 2014 Nov 12.

PMID:
25392324
11.

NMO spectrum of disorders: a paradigm for astrocyte-targeting autoimmunity and its implications for MS and other CNS inflammatory diseases.

Vaknin-Dembinsky A, Karussis D, Avichzer J, Abramsky O.

J Autoimmun. 2014 Nov;54:93-9. doi: 10.1016/j.jaut.2014.05.004. Epub 2014 Aug 14. Review.

PMID:
25129503
12.

The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.

Karussis D.

J Autoimmun. 2014 Feb-Mar;48-49:134-42. doi: 10.1016/j.jaut.2014.01.022. Epub 2014 Feb 10. Review.

PMID:
24524923
13.

The spectrum of post-vaccination inflammatory CNS demyelinating syndromes.

Karussis D, Petrou P.

Autoimmun Rev. 2014 Mar;13(3):215-24. Review.

PMID:
24514081
14.

Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy.

Petrou P, Argov A, Lennon VA, Gotkine M, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D.

Muscle Nerve. 2014 Mar;49(3):455-7. doi: 10.1002/mus.24143. Epub 2014 Jan 20. No abstract available.

PMID:
24327321
15.

Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors.

Kassis I, Petrou P, Halimi M, Karussis D.

Immunol Lett. 2013 Jul-Aug;154(1-2):70-6. doi: 10.1016/j.imlet.2013.06.002. Epub 2013 Aug 28.

PMID:
23994102
16.

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation.

Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, Abramsky O, Karussis D, Rosenmann H.

Exp Neurol. 2013 Oct;248:451-6. doi: 10.1016/j.expneurol.2013.07.006. Epub 2013 Jul 20.

PMID:
23876516
17.

Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1(G93A) mouse model.

Lilo E, Wald-Altman S, Solmesky LJ, Ben Yaakov K, Gershoni-Emek N, Bulvik S, Kassis I, Karussis D, Perlson E, Weil M.

Hum Mol Genet. 2013 Dec 1;22(23):4720-5. doi: 10.1093/hmg/ddt325. Epub 2013 Jul 7.

PMID:
23836781
18.

Hematopoietic stem cell transplantation in multiple sclerosis.

Karussis D, Petrou P, Vourka-Karussis U, Kassis I.

Expert Rev Neurother. 2013 May;13(5):567-78. doi: 10.1586/ern.13.36. Review.

PMID:
23621313
19.

[Inflammation of the optic nerve: when it should be considered as neuromyelitis optica--the experience of the Department of Neurology at Hadassah Hospital].

Vaknin-Dembinsky A, Levin N, Raz N, Abramsky O, Karussis D, Brill L, Petrou P, Ovadia H.

Harefuah. 2013 Feb;152(2):101-5, 122. Hebrew.

PMID:
23513502
20.

Immunotherapy of multiple sclerosis: the state of the art.

Karussis D.

BioDrugs. 2013 Apr;27(2):113-48. doi: 10.1007/s40259-013-0011-z. Review.

PMID:
23423844

Supplemental Content

Loading ...
Support Center